In situ analysis of p16/INK4 promoter hypermethylation in esophageal carcinoma and gastric carcinoma

Chin J Dig Dis. 2004;5(4):149-55. doi: 10.1111/j.1443-9573.2004.00172.x.

Abstract

Objective: Inactivation of the tumor suppressor gene by CpG hypermethylation is a common event in a variety of tumors. The present study was designed to be a comprehensive analysis of p16/INK4 methylation in carcinomas of the upper digestive tract.

Methods: Series of esophageal carcinomas (34 cases) and gastric carcinomas (25 cases) were examined for CpG methylation in p16/INK4 using methylation-specific PCR (MSP). The tissue sections underwent MSP in situ and were then examined microscopically. Immunohistochemical detection of the expression of p16 in the tumor specimens was also performed.

Results: Immunohistochemistry detected positive p16 expression in 8 cases of esophageal squamous cell carcinoma and 15 cases of gastric carcinoma. In esophageal carcinoma, hypermethylation of the p16/INK4 promoter region was detected in 5 cases without statistical correlation with its loss of expression, whereas in the gastric carcinomas, p16 expression was positively correlated with the T-classification (r = 0.488, P = 0.01); p16/INK4 methylation was identified in 8 cases. In addition, p16 expression was lower in the methylated samples than in the non-methylated samples (25% vs 76.47%, P = 0.03). Analysis of the MSP-in-situ sections showed that the distribution of methylated cells in esophageal carcinoma differed from that in gastric carcinoma.

Conclusion: The role of DNA methylation in the silence of p16/INK4 may different between these two types of upper digestive tract tumor.

MeSH terms

  • Carcinoma / genetics*
  • Cyclin-Dependent Kinase Inhibitor p16 / genetics*
  • DNA Methylation*
  • Esophageal Neoplasms / genetics*
  • Genes, p16*
  • Humans
  • Immunohistochemistry
  • Polymerase Chain Reaction
  • Promoter Regions, Genetic
  • Stomach Neoplasms / genetics*

Substances

  • Cyclin-Dependent Kinase Inhibitor p16